CBRE GROUP, INC.

CBRE

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Eventide Asset ManagementNEWFeb 13, 2026

Shares: 5,102Value: $833K

**SIGNAL NOTE: Eventide/CBRE Position Initiation** Eventide's $833K CBRE entry is notable given the fund's biotech-focused mandate—CBRE's real estate services to life sciences organizations (lab space, clinical trial facilities) suggests positioning for biotech sector expansion rather than a core healthcare thesis. This signals confidence in sustained biopharma real estate demand, potentially ahead of expected clinical trial acceleration or manufacturing capacity needs in 2024-2025.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CPRT1 fund DECK1 fund LITE1 fund NTAP1 fund GPI1 fund IMMX1 fund PI1 fund UNP1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: